Nuvalent
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company aims to overcome the limitations of existing therapies for clinically proven kinase targets. They develop innovative small molecules to address various cancer challenges. Nuvalent is advancing a robust pipeline with investigational candidates for diffe
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 170
- Industries
- Biotechnology, Healthcare, Health Care
- Website
- http://www.nuvalent.com/
- Company page
Recent activity at Nuvalent
- : SEC 8-K (5.02): On July 12, 2026, in accordance with the Merger Agreement, all directors of the Company, including James R. Porter, Ph.D., Grant C. Bogle, and others, resigned from their positions as members of the board of directors as part of a corporate merger. Simultaneously, Justin T. Huang and Kevin T. Ryan, directors of the Purchaser prior to the merger, were appointed as directors of the Company. Additionally, all incumbent officers ceased their roles and the officers of the Purchaser took over, with Justin T. Huang assuming the position of President and Secretary. This restructuring is a strategic move in the context of the merger finalized at the Effective Time.
- : SEC 8-K (1.01): On June 9, 2026, Nuvalent, Inc. entered into a Merger Agreement with GlaxoSmithKline LLC and its subsidiary, Harmony Row Acquisition Co. The agreement outlines a tender offer to purchase all issued shares of Nuvalent’s Class A and Class B Common Stock at a price of $124.00 per share. The transaction's success hinges on the tender of a majority of Class A shares, and it will close subject to regulatory approvals, including antitrust laws. If conditions are met, the acquisition will be completed without a stockholder vote, with the merger allowing GlaxoSmithKline to continue as the surviving entity.
- : SEC 8-K (8.01): On April 7, 2026, Nuvalent, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its drug neladalkib, aimed at treating patients with advanced ALK-positive non-small cell lung cancer who have previously been treated with tyrosine kinase inhibitors. This submission represents a significant step in the company’s efforts to develop treatments for this specific cancer type. The filing with the FDA is crucial for the potential market access and revenue generation of neladalkib upon approval. The exact timing of the review process and any conditions related to the NDA will play an important role in the future of the drug's commercialization.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On December 9, 2025, Dr. Matthew Shair resigned from the Board of Directors of Nuvalent, Inc., effective immediately, without any disagreements with the company. Following this, on December 10, 2025, Ron Squarer was elected as a new Class II director of the Board, as recommended by the Nominating and Corporate Governance Committee. Mr. Squarer, deemed an 'independent' director, will receive a total compensation package valued at $600,000, including stock options and restricted stock units with specific vesting schedules. His election and compensation arrangements are aimed at enhancing board independence and governance, reflecting the company's strategic priority of maintaining a robust leadership structure.
- : SEC 8-K (1.01): On November 18, 2025, Nuvalent, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co. for a public offering of 4,950,496 shares of Class A common stock at a public price of $101.00 per share. The underwriters will purchase the shares at $95.445 each, with expected net proceeds to the company of approximately $471.9 million. Additionally, the selling stockholders granted an option to the underwriters to purchase up to 742,574 additional shares. The closing of the offering is anticipated to occur on November 20, 2025, subject to customary conditions. The filing includes details on customary representations and warranties, as well as indemnification obligations, ensuring standard practices in such agreements.
- : SEC 8-K (8.01): On November 17, 2025, Nuvalent, Inc. announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial. The results suggest that neladalkib may provide a significant treatment option for this patient population, showcasing its recommended Phase 2 dose of 150 mg once daily. The data includes preliminary findings from the Phase 2 exploratory cohort for TKI-naïve patients, marking a critical step in evaluating the efficacy of the drug. This announcement has strategic implications for the company in terms of advancing its clinical development pipeline and engaging potential investors.
- : SEC 8-K (8.01): On November 17, 2025, Nuvalent, Inc. announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the ongoing ALKOVE-1 Phase 1/2 clinical trial. This includes preliminary data from an exploratory cohort for TKI-naïve patients. The trial aims to establish the recommended Phase 2 dose of 150 mg once daily, and as of August 29, 2025, 781 patients had participated across both trial phases. The results highlight efficacy measures such as objective response rate and duration of response, focusing on a pivotal analysis of 253 TKI pre-treated patients by September 30, 2024. This data is crucial as it may have implications for treatment options in a population previously shown to have limited options, especially after lorlatinib treatment.
- : Nuvalent Promotes Jason Waters to Senior Vice President, Commercial
- : Nuvalent, Inc.
Nuvalent funding history
| Date | Round | Amount |
|---|---|---|
| May 2021 | Venture | $135.0M |
| May 2021 | Series B | $135.0M |
Leadership
- R. James, Executive Officer, Director
- Matthew Shair, Director
- Cameron Wheeler, Director
- Robert Jackson, Director
- Joseph Pearlberg, Director
- Gary Gilliland, Director
- Andrew Hack, Director
- Alexandra Balcom, Chief Financial Officer
- Jason Waters, Vice President Of Commercial
- Alex Balcom, Executive Officer
Verified email and direct lines for Nuvalent’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Nuvalent files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Nuvalent
- Parabilis Medicines · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Pelthos Therapeutics · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Biofrontera · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Nuvalent: questions and answers
What does Nuvalent do?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company aims to overcome the limitations of existing therapies for clinically proven kinase targets. They develop innovative small molecules to address various cancer challenges. Nuvalent is advancing a robust pipeline with investigational candidates for diffe
Where is Nuvalent headquartered?
Nuvalent is headquartered in Cambridge, Massachusetts, United States.
How many employees does Nuvalent have?
Nuvalent has about 170 employees.
Has Nuvalent raised funding?
Yes. Fundz has recorded 2 funding events for Nuvalent. The most recent, $135.0M, was in May 2021.
Who leads Nuvalent?
Jason Waters is a Vice President Of Commercial at Nuvalent.
What is the latest news on Nuvalent?
On Jul 15, 2026, SEC 8-K (5.02): On July 12, 2026, in accordance with the Merger Agreement, all directors of the Company, including James R. Porter, Ph.D., Grant C. Bogle, and others, resigned from their positions as members of the board of directors as part of a corporate merger. Simultaneously, Justin T. Huang and
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy